More than just reassurance on tiotropium safety

New England Journal of Medicine

Volumn 369, Issue 16, 2013, Pages 1555-1556

  Jenkins, Christine R ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; EDITORIAL; EXERCISE; HUMAN; LUNG FUNCTION; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 84885794300     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1310107     Document Type: Editorial

References (8)

1. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215.
2. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010;363:1097-9.
3. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50. [Erratum, JAMA 2009;301:1227-30.]
4. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009;103:1421-9.
5. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30.
6. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-55.
7. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285.
8. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491-501.